EVOLUS, INC. Contract Liability (Deferred Revenue)
EVOLUS, INC. (EOLS) had Contract Liability (Deferred Revenue) of $11.59 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability, Current $11.59M.
- 2026-03-31: Contract with Customer, Liability, Current $8.62M.
- 2025-12-31: Contract with Customer, Liability, Current $11.55M.
- 2025-09-30: Contract with Customer, Liability, Current $8.58M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $11.59M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $8.62M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $11.55M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $8.58M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $8.73M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $7.57M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $14.45M 10-K · filed 2026-03-03 |
| 2024-09-30 | $13.23M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $11.79M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $8.71M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $11.03M 10-K · filed 2025-03-04 |
| 2023-09-30 | $8.78M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $8.94M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $6.99M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $9.01M 10-K · filed 2025-03-04 |
| 2022-09-30 | $10.19M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $6.69M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $4.99M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $7.93M 10-K · filed 2023-03-08 |
| 2021-09-30 | $5.75M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $4.53M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $3.11M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $3.08M 10-K · filed 2022-03-03 |
| 2020-09-30 | $2.37M 10-Q · filed 2020-10-29 |
| 2019-12-31 | $1.71M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |